Bispecific antibody · Immune activation, directed at B7-H3 (CD276) and CD28 · developed by Xencor
XmAb808 is a bispecific antibody that binds B7-H3 (CD276) on certain tumor cells and CD28 on cytotoxic T-lymphocytes. By engaging both, it activates and redirects T cells to B7-H3-expressing tumor cells. It is being studied in multiple solid tumors, including ovarian, head and neck, lung, breast, and colorectal cancers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07593092 | Phase 1 | Ovarian Cancer | Recruiting | XNCR |
| NCT05585034 | Phase 1 | Head and Neck Squamous Cell Carcinoma | Completed | XNCR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Ovarian CancerCastration-resistant Prostate CancerColorectal CancerHead and Neck Squamous Cell CarcinomaMelanoma Excluding Uveal MelanomaNon-small Cell Lung Cancer, Squamous or Non-squamousOvarian Cancer, EpithelialRenal Cell Carcinoma, Clear CellTNBC - Triple-Negative Breast CancerUrothelial Carcinoma
Updated Nov 1, 2026. Something wrong or missing? Report it on the XNCR page.
See XNCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
XNCR catalysts and pipeline →